[Form 4] MARAVAI LIFESCIENCES HOLDINGS, INC. Insider Trading Activity
Christine Dolan, an officer at MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI), reported a routine tax-withholding transaction. On March 16, 2026, 28,661 shares of Class A common stock were withheld at $3.08 per share to cover tax obligations related to the vesting of restricted stock units. Following this disposition, Dolan directly holds 420,312 shares of Class A common stock.
Maravai (MRVI) General Counsel has 39,976 shares withheld for taxes
Maravai Lifesciences Holdings General Counsel Kurt Oreshack had 39,976 shares of Class A common stock withheld at $3.08 per share to cover tax obligations related to the vesting of restricted stock units. This transaction was a routine tax-withholding and not an open-market sale. Following this non-market disposition, Oreshack directly holds 384,991 shares of Maravai stock.
After $231M loss, Maravai targets $200M+ in 2026 revenue
Maravai LifeSciences reported a net loss of $230.8 million for the full year 2025, with Q4 revenue reaching $49.9 million. Despite the losses, the company provided 2026 revenue guidance of $200 million to $210 million and Adjusted EBITDA guidance of $18 million to $20 million, signaling a focus on operational excellence and revenue growth. The firm also announced organizational restructuring and operating cost reductions.
Analysts Offer Insights on Healthcare Companies: Veracyte (VCYT), Maravai Lifesciences Holdings (MRVI) and Sarepta Therapeutics (SRPT)
This article provides analyst insights on three healthcare companies: Veracyte (VCYT), Maravai Lifesciences Holdings (MRVI), and Sarepta Therapeutics (SRPT). Veracyte received a reiterated Buy rating from William Blair and an upgrade to Buy from TipRanks – DeepSeek. Maravai Lifesciences Holdings maintained a Hold rating from Guggenheim and William Blair, while Sarepta Therapeutics received a Buy rating from Mizuho Securities.
Maravai LifeSciences Holdings (MRVI) Posts US$130.8m TTM Loss Challenging Margin Recovery Narratives
Maravai LifeSciences Holdings (MRVI) reported a US$130.8 million trailing twelve-month loss for FY 2025, with revenue of US$185.7 million, sparking concerns about its path to profitability. The company's recent quarterly losses and a five-year pattern of widening losses challenge narratives of margin recovery, despite management's efforts to implement over US$50 million in annualized cost savings. While the stock trades at a P/S of 2.8x, lower than peers, and has a DCF fair value of US$7.10 against a current price of US$3.56, analysts remain divided on its future prospects given its unprofitability and slower revenue growth compared to the US market.
Maravai Lifesciences Reports Fourth Quarter and Full Year 2025 Financial Results
Maravai LifeSciences (NASDAQ: MRVI) reported its financial results for the fourth quarter and full year ended December 31, 2025, exceeding revenue expectations and returning to positive Adjusted EBITDA in Q4. The company announced quarterly revenue of $49.9 million and an annual revenue of $185.7 million, with a net loss of $(63.0) million and $(230.8) million respectively. Maravai also provided full-year 2026 guidance, projecting revenue between $200 million and $210 million and Adjusted EBITDA between $18 million and $20 million, driven by a focus on operational excellence and revenue growth.
Maravai LifeSciences (NASDAQ: MRVI) posts 2025 loss but targets 2026 EBITDA rebound
Maravai LifeSciences (NASDAQ: MRVI) reported a challenging 2025 with significant revenue decline and a net loss, primarily due to reduced demand for its CleanCap vaccine orders. Despite this, the company saw slightly positive Adjusted EBITDA in Q4 2025, driven by cost reductions. Looking ahead, Maravai projects a rebound in 2026, guiding for increased revenue and a return to positive Adjusted EBITDA, as it focuses on operational excellence and growth.
Maravai Lifesciences Reports Fourth Quarter and Full Year 2025 Financial Results
Maravai LifeSciences (NASDAQ: MRVI) reported its fourth quarter and full year 2025 financial results, exceeding revenue expectations and returning to positive Adjusted EBITDA in Q4. The company announced full year 2026 revenue guidance of $200 million to $210 million and Adjusted EBITDA guidance of $18 million to $20 million, driven by operational excellence and cost reduction efforts. Financial performance was impacted by a decrease in TriLink revenue due to a lack of high-volume CleanCap orders, while Cygnus revenue saw an increase.
Analysts Offer Insights on Healthcare Companies: Thermo Fisher (TMO), Phibro Animal Health (PAHC) and Unicycive Therapeutics (UNCY)
This article summarizes recent analyst ratings for three healthcare companies. Stifel Nicolaus maintained a Buy rating for Thermo Fisher (TMO) with a $700 price target, while Bank of America Securities issued a Sell rating for Phibro Animal Health (PAHC) with a $32 price target. Noble Financial reiterated a Buy rating for Unicycive Therapeutics (UNCY) with a $60 price target, noting a significant potential upside.
Investor group (NASDAQ: MRVI) reports 7.23% Maravai LifeSciences stake
An investor group has filed an amended Schedule 13G/A, reporting a beneficial ownership of 10,486,451 Class A common shares, which represents 7.23% of Maravai LifeSciences Holdings, Inc. The group includes various entities like Hudson View Holdings LLC and JD Squared Holdings II LLC, along with individuals such as Stuart Feldman. The filing explicitly certifies that the shares were not acquired to change or influence the control of Maravai LifeSciences.
Analysts Offer Insights on Healthcare Companies: Thermo Fisher (TMO), Phibro Animal Health (PAHC) and Unicycive Therapeutics (UNCY)
Analysts have provided new ratings for several healthcare companies. Stifel Nicolaus analyst Daniel Arias maintained a Buy rating on Thermo Fisher (TMO) with a $700.00 price target, suggesting a strong upside. Bank of America Securities analyst Michael Ryskin maintained a Sell rating on Phibro Animal Health (PAHC), while Noble Financial's Robert LeBoyer reiterated a Buy rating on Unicycive Therapeutics (UNCY) with a significant price target of $60.00, implying a substantial upside.
Maravai LifeSciences Holdings (NASDAQ:MRVI shareholders incur further losses as stock declines 11% this week, taking five-year losses to 90%
Maravai LifeSciences Holdings (NASDAQ:MRVI) has seen its stock price drop by 90% over the last five years, including an 11% decline this past week and 32% over the last twelve months. The company is not currently profitable, and its revenue has shrunk by 21% per year over the last five years. Despite the poor financial performance, there has been some significant insider buying in the last three months, which could be a positive sign.
MRVI SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Maravai LifeSciences Holdings, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit!
Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) on behalf of investors who purchased shares between August 7, 2024, and February 24, 2025. The lawsuit alleges that Maravai made false and misleading statements regarding its revenue recognition, internal controls, and goodwill, leading to an overstatement of its financial prospects. Shareholders with losses during this period have until May 5, 2025, to seek appointment as lead plaintiff.
Maravai ALERT: Bragar Eagel & Squire, P.C. is Investigating Maravai LifeSciences Holdings, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) on behalf of long-term stockholders. The investigation follows a class action complaint filed after Maravai announced errors in revenue recognition, a material weakness in internal controls, and a potential non-cash impairment charge related to a past acquisition, causing a significant drop in share price. The law firm is encouraging affected investors to contact them for more information.
A US$75m Market Cap Boost Pleasing ToMaravai LifeSciences Holdings Insiders
Maravai LifeSciences Holdings (NASDAQ:MRVI) experienced a 16% stock increase last week, adding US$75m to its market capitalization, which was pleasing for insiders who bought shares over the past year. Insiders, notably CEO Bernd Brust, collectively purchased US$1.9m worth of shares, indicating a positive outlook although the company did not make a profit in the last year. Insider ownership stands at 2.5%, aligning management's interests with smaller shareholders.
MRVI INVESTOR ALERT: Kirby McInerney LLP Reminds Maravai Lifesciences Holdings, Inc. Investors of Looming Lead Plaintiff Deadline in Class Action Lawsuit
Kirby McInerney LLP is reminding investors of Maravai Lifesciences Holdings, Inc. (NASDAQ:MRVI) that the lead plaintiff deadline for a federal securities class action lawsuit is May 5, 2025. The lawsuit alleges that Maravai failed to disclose inadequate internal controls over revenue recognition and an overstatement of goodwill, leading to a significant stock price decline on February 25, 2025, after the company announced delays in its earnings release and annual report due to an identified error in revenue recognition and a potential non-cash impairment charge. Investors who purchased Maravai securities during the Class Period (August 7, 2024, through February 24, 2025) are encouraged to contact the law firm to discuss their rights.
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Maravai Lifesciences Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRVI
Rosen Law Firm is reminding investors of Maravai Lifesciences Holdings, Inc. (NASDAQ:MRVI) that the lead plaintiff deadline for a securities class action lawsuit is May 5, 2025. The lawsuit alleges that Maravai made false and misleading statements regarding its financial reporting and goodwill. Investors who purchased Maravai securities between August 7, 2024, and February 24, 2025, are encouraged to secure counsel.
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Maravai LifeSciences Holdings, Inc. (MRVI) Shareholders
Levi & Korsinsky has filed a securities class action lawsuit against Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) on behalf of shareholders who suffered losses due to alleged securities fraud between August 7, 2024, and February 24, 2025. The lawsuit claims that Maravai made false statements and concealed issues regarding its internal controls over financial reporting, leading to inaccurate revenue recognition and an overstatement of goodwill. Shareholders affected during this period are encouraged to seek information on potential recovery.
Maravai LifeSciences Reports Third Quarter 2025 Financial Results
Maravai LifeSciences (NASDAQ: MRVI) announced its third quarter 2025 financial results, reporting revenue of $41.6 million, a net loss of $(45.1) million, and Adjusted EBITDA of $(10.8) million. Despite a decline in Nucleic Acid Production revenue due to fewer high-volume CleanCap orders, the company projects full-year 2025 revenue of approximately $185.0 million and anticipates double-digit sequential revenue growth for TriLink in Q4 2025. The company leadership expressed confidence in their restructuring initiatives to deliver attractive financial results for the remainder of 2025 and 2026.
MARAVAI INVESTIGATION REMINDER: Bragar Eagel & Squire, P.C.
Bragar Eagel & Squire, P.C. is continuing its investigation into Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) on behalf of long-term stockholders. This follows a class action complaint alleging that Maravai made materially false or misleading statements and failed to disclose critical information regarding revenue recognition errors and internal control weaknesses. The investigation focuses on whether Maravai's board of directors breached their fiduciary duties, especially after the company postponed its 2024 earnings release and reported a material weakness in internal controls over revenue recognition, causing a significant stock drop.
MARAVAI (MRVI) INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Reminds Investors of the Investigation into Maravai LifeSciences Holdings, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) on behalf of long-term stockholders following a class action complaint filed on March 3, 2025. The investigation stems from Maravai postponing its fiscal 2024 earnings and delaying its 10-K filing due to an identified error in revenue recognition of approximately $3.9 million, a material weakness in internal controls, and a potential non-cash impairment charge related to an acquisition. This news caused Maravai's share price to drop 21.70% to $3.14 on February 25, 2025.
MRVI Investors Have Opportunity to Lead Maravai LifeSciences Holdings, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today!
Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Maravai LifeSciences Holdings, Inc. Investors who purchased MRVI securities between November 10, 2020, and May 10, 2022, have until October 24, 2023, to apply to be lead plaintiff. The lawsuit alleges that Maravai made false and misleading statements regarding its business, operations, and prospects, and failed to disclose that its COVID-19 revenue was unsustainable and would decline.
Levi & Korsinsky Notifies Shareholders of Maravai LifeSciences Holdings, Inc.(MRVI) of a Class Action Lawsuit and an Upcoming Deadline
Levi & Korsinsky has notified shareholders of Maravai LifeSciences Holdings, Inc. (MRVI) about a class action lawsuit. This notice highlights an upcoming deadline for shareholders to potentially participate in the lawsuit. The specific details of the lawsuit and the deadline are not provided in this snippet.
Maravai LifeSciences Holdings, Inc. (MRVI) Faces Securities Class Action After Delaying Q4 and FY 2024 Earnings Release, Admitting to Improper Revenue Recognition – Hagens Berman
Hagens Berman has announced a securities class action lawsuit against Maravai LifeSciences Holdings, Inc. (MRVI) due to the company's delayed Q4 and FY 2024 earnings report and admission of improper revenue recognition. This revelation led to a significant 23% drop in Maravai's stock price. Investors who suffered losses are encouraged to contact Hagens Berman for more information on the lawsuit and their potential claims.
Maravai LifeSciences Holdings, Inc. Class Action: The Gross Law Firm Reminds Maravai LifeSciences Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 5, 2025 – MRVI
The Gross Law Firm is reminding investors of Maravai LifeSciences Holdings, Inc. (MRVI) about a pending class action lawsuit. Investors who purchased MRVI securities between November 10, 2022, and May 7, 2024, are encouraged to contact the firm to learn about their rights. The deadline to apply to be a lead plaintiff in the lawsuit is May 5, 2025.
Maravai LifeSciences Announces Organizational Restructuring and Cost Reduction Initiatives Aiming for $50 Million in Annual Savings | MRVI Stock News
Maravai LifeSciences announced an organizational restructuring and cost reduction initiatives targeting over $50 million in annual savings after reporting a 31.7% year-over-year revenue decline in Q2 2025. The company, which saw a 5% increase in its base business revenue, expects to achieve positive adjusted EBITDA and free cash flow by the second half of 2026. Leadership changes include Bernd Brust as CEO and Raj Asarpota as CFO, as Maravai aims to realign its cost structure and minimize operational disruption.
The Gross Law Firm Notifies Shareholders of Maravai LifeSciences Holdings, Inc. (MRVI) of a Class Action Lawsuit and an Upcoming Deadline
The Gross Law Firm has issued a notice to shareholders of Maravai LifeSciences Holdings, Inc. (MRVI) regarding a class action lawsuit. The lawsuit alleges that Maravai LifeSciences Holdings, Inc. issued materially false and misleading statements concerning its revenue recognition and goodwill. Shareholders who purchased MRVI shares between August 7, 2024, and February 24, 2025, are encouraged to contact the firm by the May 5, 2025 deadline to potentially be appointed as lead plaintiff.
ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Maravai Lifesciences Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRVI
This article from Rosen Law Firm encourages investors in Maravai Lifesciences Holdings, Inc. (MRVI) to secure legal counsel due to an approaching deadline in a securities class action lawsuit. Investors who purchased MRVI securities between May 6, 2021, and November 10, 2023, may be eligible to join the class action. The lawsuit alleges that Maravai made materially false and misleading statements regarding its business, operations, and prospects.
MARAVAI LIFESCIENCES INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Maravai LifeSciences Holdings, Inc. - MRVI
Kahn Swick & Foti, LLC (KSF), led by former Louisiana Attorney General Charles C. Foti, Jr., has launched an investigation into Maravai LifeSciences Holdings, Inc. (NasdaqGS: MRVI). This investigation follows Maravai's disclosure of delayed annual report filing due to a revenue recognition error and potential impairment charge, which led to an ongoing securities class action lawsuit against the company and its executives. KSF is examining whether Maravai's officers and directors breached their fiduciary duties or violated laws, inviting long-term shareholders to contact them regarding their legal rights.
MRVI Stock Drop: What Investors Should Know
Maravai LifeSciences Holdings Inc. (MRVI) stock dropped significantly by -7.56% on March 19, 2025, amidst multiple class action lawsuits alleging securities fraud, false financial reporting, and inadequate internal controls. The company is facing scrutiny over overstated goodwill, inaccurate revenue recognition, and a Q4 adjusted loss of $0.06 per diluted share. Despite substantial liquidity and total assets, legal challenges and troubling financial signals are creating uncertainty and a cautious sentiment among investors, with one analyst advising a level-headed trading strategy over emotional reactions.
Maravai LifeSciences Reports Second Quarter 2025 Financial Results
Maravai LifeSciences reported its second quarter 2025 financial results, showing a 31.7% decrease in total revenue year-over-year, primarily due to lower CleanCap orders. The company announced a major organizational restructuring and cost reduction plan targeting over $50 million in annualized savings and appointed a new CEO and CFO to drive innovation and improve financial performance. Maravai expects a reduction in net loss, positive Adjusted EBITDA, and positive free cash flow by the second half of 2026, while withdrawing its full-year 2025 revenue guidance during its business review.
Maravai LifeSciences Reports Second Quarter 2025 Financial Results
Maravai LifeSciences (NASDAQ: MRVI) reported its second-quarter 2025 financial results, with revenue of $47.4 million, a net loss of $(69.8) million, and adjusted EBITDA of $(10.4) million. The company announced an organizational restructuring and cost reduction initiatives aimed at over $50 million in annualized savings, and it expects a net loss reduction, positive Adjusted EBITDA, and positive free cash flow by the second half of 2026. Maravai also appointed Bernd Brust as CEO and Raj Asarpota as CFO to drive innovation and performance.
Maravai Launches Major $50M Restructuring Plan as New CEO Takes Helm Amid Earnings Challenge
Maravai LifeSciences reported challenging Q2 2025 financial results with a significant revenue decline and a net loss, including a goodwill impairment. In response, new CEO Bernd Brust and CFO Raj Asarpota announced a major restructuring plan targeting over $50 million in annualized cost savings. The company has withdrawn its 2025 guidance and aims for net loss reduction, positive Adjusted EBITDA, and positive free cash flow by the second half of 2026.
MRVI SEC Filings - Maravai Lifesciences Holdings, Inc. 10-K, 10-Q, 8-K Forms
This page provides access to Maravai Lifesciences Holdings (MRVI) SEC filings, including annual/quarterly reports and material event forms, for investors. It highlights recent filings such as a CFO appointment, insider stock awards for multiple directors, and the associated compensation details. The platform also offers AI-powered tools to summarize these regulatory disclosures.
Maravai LifeSciences Appoints Bernd Brust as CEO, Succeeding Trey Martin
Maravai LifeSciences has appointed Bernd Brust as its new CEO and a board member, replacing William "Trey" Martin III. Brust brings over 30 years of experience in the life sciences industry, with a focus on driving innovation and financial performance. The company aims to expand its market leadership in mRNA and bioprocess impurity detection under Brust's leadership, while reaffirming its commitment to customer-centric solutions.
Levi & Korsinsky Reminds Maravai LifeSciences Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 5, 2025 - MRVI
Levi & Korsinsky LLP reminds investors of Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) about a pending class action lawsuit with a lead plaintiff deadline of May 5, 2025. The lawsuit alleges securities fraud due to misstatements and concealment regarding Maravai's internal controls, revenue recognition, and overstated goodwill between August 7, 2024, and February 24, 2025. Shareholders who suffered losses during this period are encouraged to seek information about their potential recovery rights.
MRVI Investors Have Opportunity to Lead Maravai LifeSciences Holdings, Inc. Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm is reminding investors of a class action lawsuit against Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) for alleged securities fraud. Investors who purchased the company's securities between August 7, 2024, and February 24, 2025, are encouraged to contact the firm before May 5, 2025, to discuss their rights and participate in the lawsuit. The complaint alleges that Maravai made false and misleading statements, failed to maintain adequate internal controls, improperly recognized revenue, and overstated its goodwill.
MRVI Investors Have Opportunity to Lead Maravai LifeSciences Holdings, Inc. Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm has announced a class action lawsuit against Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) for alleged securities fraud, encouraging investors who purchased shares between August 7, 2024, and February 24, 2025, to contact the firm by May 5, 2025. The lawsuit claims Maravai made false and misleading statements, failed to maintain adequate internal controls, improperly recognized revenue, and overstated its goodwill, leading to investor losses.
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Maravai LifeSciences Holdings, Inc. of Class Action Lawsuit and Upcoming Deadlines - MRVI
Pomerantz LLP has filed a class action lawsuit against Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) on behalf of investors who suffered losses. The lawsuit stems from Maravai's announcement of postponing its fiscal 2024 earnings release and delaying its annual report due to an identified error in revenue recognition and a material weakness in internal controls, which caused the stock price to drop significantly. Investors have until May 5, 2025, to apply to be appointed as Lead Plaintiff.
May 5, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against MRVI
Levi & Korsinsky LLP has announced a May 5, 2025, deadline for shareholders to join a class action lawsuit against Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI). The lawsuit aims to recover losses for shareholders who were allegedly affected by securities fraud concerning inaccurate revenue recognition and overstated goodwill between August 7, 2024, and February 24, 2025. Shareholders who suffered losses are encouraged to contact the firm to learn about their rights to recovery.
The Gross Law Firm Notifies Maravai LifeSciences Holdings, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - MRVI
The Gross Law Firm has issued a notice to shareholders of Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) regarding a class action lawsuit. Investors who purchased shares between August 7, 2024, and February 24, 2025, are encouraged to contact the firm, as the deadline to seek lead plaintiff appointment is May 5, 2025. The lawsuit alleges that Maravai made materially false and/or misleading statements, particularly regarding its revenue recognition, overstating goodwill during fiscal 2024.
Maravai LifeSciences (MRVI) Reports Weak Q4, Faces Investor Class Action – Hagens Berman
Maravai LifeSciences (MRVI) reported disappointing Q4 2024 earnings, missing analyst expectations and leading to a significant price target cut by Stifel. The company is also facing a securities class action lawsuit alleging improper accounting related to revenue recognition and an overstatement of goodwill. Hagens Berman is investigating these claims, encouraging investors with losses to contact the firm before the May 5th deadline, and highlighting material weaknesses in Maravai's internal controls.
Class Action Filed Against Maravai LifeSciences Holdings, Inc. (MRVI) Seeking Recovery for Investors - Contact Levi & Korsinsky
A class action lawsuit has been filed against Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) seeking to recover losses for investors who suffered adverse effects due to alleged securities fraud between August 7, 2024, and February 24, 2025. The lawsuit claims that Maravai lacked adequate internal controls over financial reporting, inaccurately recognized revenue, and overstated its goodwill, leading to materially misleading statements about the company's business. Investors are encouraged to contact Levi & Korsinsky, LLP for information about their rights to seek recovery.
Levi & Korsinsky Reminds Maravai LifeSciences Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 5, 2025 - MRVI
Levi & Korsinsky, LLP has notified investors of Maravai LifeSciences (NASDAQ: MRVI) about a pending class action securities lawsuit. The lawsuit alleges securities fraud between August 7, 2024, and February 24, 2025, due to issues like inadequate internal controls over revenue recognition and overstated goodwill. Investors who suffered losses have until May 5, 2025, to request to be appointed as lead plaintiff.
MRVI Deadline in 4 Days: Kessler Topaz Meltzer & Check, LLP Reminds Maravai LifeSciences Holdings, Inc. (MRVI) Investors of Filing Deadline in Class Action Lawsuit
Kessler Topaz Meltzer & Check, LLP is reminding investors of Maravai LifeSciences Holdings, Inc. (MRVI) that the lead plaintiff deadline in a securities class action lawsuit is May 5, 2025. The lawsuit alleges that Maravai made materially false and misleading statements about its revenue recognition and goodwill between August 7, 2024, and February 24, 2025. Investors who suffered losses are encouraged to contact the firm to learn more about seeking lead plaintiff appointment.
Lost Money on Maravai LifeSciences Holdings, Inc.(MRVI)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm
The Gross Law Firm has issued a notice to shareholders of Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) to join a class action lawsuit. This suit alleges that Maravai made false or misleading statements regarding its revenue recognition, overstated goodwill, and lacked adequate internal controls, leading to artificially inflated stock prices. Shareholders who purchased MRVI shares between August 7, 2024, and February 24, 2025, are encouraged to register for the class action before the May 5, 2025, deadline to seek lead plaintiff appointment.
Levi & Korsinsky Reminds Maravai LifeSciences Holdings, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 5, 2025 - MRVI
Levi & Korsinsky LLP has reminded investors of Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) about a pending class action lawsuit with a lead plaintiff deadline of May 5, 2025. The lawsuit alleges that Maravai made false statements and/or concealed issues related to inadequate internal controls over financial reporting, inaccurate revenue recognition, and overstated goodwill between August 7, 2024, and February 24, 2025. Investors who suffered losses during this period are encouraged to seek more information about their rights.
Class Action Filed Against Maravai LifeSciences Holdings, Inc. (MRVI) Seeking Recovery for Investors - Contact Levi & Korsinsky
A class action lawsuit has been filed against Maravai LifeSciences Holdings, Inc. (MRVI) on behalf of investors who suffered losses between August 7, 2024, and February 24, 2025. The lawsuit alleges that Maravai made false statements concerning its internal controls over financial reporting, revenue recognition, and overstating goodwill. Investors are encouraged to contact Levi & Korsinsky, LLP to learn about their rights to potentially recover losses.
Levi & Korsinsky Reminds Maravai LifeSciences Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 5, 2025 - MRVI
Levi & Korsinsky LLP announced a pending class action lawsuit against Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) for alleged securities fraud from August 7, 2024, to February 24, 2025. The lawsuit claims Maravai lacked adequate internal controls, inaccurately recognized revenue, and overstated goodwill, leading to misleading statements about the company's prospects. Investors who suffered losses are encouraged to seek information on recovering their investments before the May 5, 2025, lead plaintiff deadline.
Maravai LifeSciences Holdings, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before May 5, 2025 to Discuss Your Rights - MRVI
Levi & Korsinsky, LLP has filed a class action securities lawsuit against Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) on behalf of investors who suffered losses between August 7, 2024, and February 24, 2025. The lawsuit alleges that Maravai LifeSciences made false statements and concealed issues related to inadequate internal controls over revenue recognition and overstated goodwill. Investors have until May 5, 2025, to request to be appointed lead plaintiff in the case.
